

RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS



E. TEJEDOR TEJADA¹, J. PERALTA ALVAREZ¹, B. GOMEZ PEREZ¹, S. TENA MESTRE¹, S. BALSELLS VIVES¹, M. DE RIBA SOLER¹, M. BOILLOS FERNANDEZ¹, A. TORRENT RODRIGUEZ¹, T. LIZONDO LOPEZ¹, D. SOY MUNER

¹Pharmacy Service. Division of Medicines. Hospital Clínic de Barcelona - Universitat de Barcelona

Background and Importance

The main challenge in clinical trials is to detect poor adherence to oral treatments which may influence on treatment effectiveness. Therefore, a tool is needed to help us stratify patients according to the risk of non-compliance

Aim and Objectives

To assess adherence in patients with oral experimental treatment and validate a predefined score to detect patients with poor or non-adherence.

Materials and Methods

An experimental, prospective study was conducted, with mainly oncohaematological patients, in a clinical trials unit of a tertiary hospital. A scoring was designed to detect non-adherence. Risk level of non-adherence was considered high (4-7), medium (3) and low (1-2).

Results








35 patients (63,4 years±15)

VARIABLE DATA	DATA COLLECTED
Score No-adherence	2,2
>1 CT drug	23,3%
>1 drug out of CT	85,4%
Attendance at consultation	73% accompained
	8% Another person





- 95% of patients no concerns on drug administration were detected
- Real adherence rate of 92%.

Conclusion and Relevance

■ Clinical trial patients included in this study showed good adherence to the experimental treatment. However, a larger sample size might be needed to verify these results.

